Biotest has obtained positive pre-clinical data
indicating the potential of BT-061 for the treatment of multiple sclerosis
(MS).
Current scientific publications by respected academic research groups show that the regulatory T-cells in particular play a central part in the development and progression of MS; impairment of their function in the patient appears to be causally linked with the disease. The monoclonal antibody BT-061 specifically activates regulatory T-cells. The pre-clinical data that have now been obtained show that BT-061 reinforces the function of regulatory T-cells derived from MS patients........... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397